OBJECTIVE: Tumours with neuroendocrine differentiation frequently express chromogranin A, synaptophysin and somatostatin receptors. The role of neuroendocrine differentiation in head and neck squamous cell carcinoma is not yet clear. METHOD: The presence of chromogranin A, synaptophysin and somatostatin receptors was studied immunohistochemically in 78 head and neck squamous cell carcinoma specimens. RESULTS: Sparse chromogranin A expression was found in 41 per cent, associated with high chromogranin A messenger RNA expression and the presence of dense core granules. Low synaptophysin expression was found in 18 per cent. The highest staining scores were found for somatostatin receptor 5 (82 per cent), followed by somatostatin receptor 1 (69 per cent) and somatostatin receptor 2 (54 per cent), whereas somatostatin receptors 3 and 4 expression was low. Expression was not correlated with tumour stage or survival. CONCLUSION: Cells with neuroendocrine differentiation are sparsely scattered in some head and neck squamous cell carcinomas. Their pathophysiological role is elusive. In contrast, somatostatin receptor and particularly somatostatin receptor 5 expression is frequent in head and neck squamous cell carcinoma. Somatostatin receptor expression is not considered to indicate neuroendocrine differentiation in head and neck squamous cell carcinoma.
OBJECTIVE: Tumours with neuroendocrine differentiation frequently express chromogranin A, synaptophysin and somatostatin receptors. The role of neuroendocrine differentiation in head and neck squamous cell carcinoma is not yet clear. METHOD: The presence of chromogranin A, synaptophysin and somatostatin receptors was studied immunohistochemically in 78 head and neck squamous cell carcinoma specimens. RESULTS: Sparse chromogranin A expression was found in 41 per cent, associated with high chromogranin A messenger RNA expression and the presence of dense core granules. Low synaptophysin expression was found in 18 per cent. The highest staining scores were found for somatostatin receptor 5 (82 per cent), followed by somatostatin receptor 1 (69 per cent) and somatostatin receptor 2 (54 per cent), whereas somatostatin receptors 3 and 4 expression was low. Expression was not correlated with tumour stage or survival. CONCLUSION: Cells with neuroendocrine differentiation are sparsely scattered in some head and neck squamous cell carcinomas. Their pathophysiological role is elusive. In contrast, somatostatin receptor and particularly somatostatin receptor 5 expression is frequent in head and neck squamous cell carcinoma. Somatostatin receptor expression is not considered to indicate neuroendocrine differentiation in head and neck squamous cell carcinoma.
Authors: Volker H Schartinger; József Dudás; Clemens Decristoforo; Christoph Url; Johannes Schnabl; Georg Göbel; Irene J Virgolini; Herbert Riechelmann; Michael Rasse; Dietmar Waitz; Daniel Putzer Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-18 Impact factor: 9.236
Authors: Álvaro Quintanal-Villalonga; Joseph M Chan; Helena A Yu; Dana Pe'er; Charles L Sawyers; Triparna Sen; Charles M Rudin Journal: Nat Rev Clin Oncol Date: 2020-03-09 Impact factor: 66.675
Authors: Volker H Schartinger; József Dudás; Christoph Url; Susanne Reinold; Irene J Virgolini; Alexander Kroiss; Herbert Riechelmann; Christian Uprimny Journal: Eur J Nucl Med Mol Imaging Date: 2014-09-17 Impact factor: 9.236
Authors: S Skvortsov; J Dudás; P Eichberger; M Witsch-Baumgartner; J Loeffler-Ragg; C Pritz; V H Schartinger; H Maier; J Hall; P Debbage; H Riechelmann; P Lukas; I Skvortsova Journal: Br J Cancer Date: 2014-05-01 Impact factor: 7.640
Authors: Daniel Dejaco; Teresa Steinbichler; Volker Hans Schartinger; Natalie Fischer; Maria Anegg; Joszef Dudas; Andrea Posch; Gerlig Widmann; Herbert Riechelmann Journal: BMJ Open Date: 2019-02-19 Impact factor: 2.692